Glioblastoma treatment and diagnostics abroad

Glioblastoma is an aggressive primary brain tumor within the adult-type diffuse glioma group. In current classification, the name refers to glioblastoma, IDH-wildtype, assigned CNS WHO grade 4. An IDH-mutant astrocytoma of grade 4 is a different diagnosis. This distinction matters because older reports may use terminology that no longer matches the current classification. A specialist integrates tissue findings and molecular results rather than relying on the scan or one test alone.

Assessment usually involves MRI and tissue obtained by surgery or biopsy when feasible. Treatment planning considers the tumor's location, neurological function, general health and relevant laboratory findings, including MGMT promoter methylation. Surgery, radiotherapy and temozolomide are commonly considered, but the safest appropriate plan varies. Discuss the aims of treatment, possible adverse effects, symptom support and follow-up with the neuro-oncology team. A second opinion can help clarify the diagnosis and available options without promising a particular outcome.

Recognizing symptoms and establishing the diagnosis

Possible symptoms include seizures, progressive weakness, headaches, or changes in speech, memory or behavior. These symptoms can have other causes and require medical assessment. A first seizure or sudden neurological deterioration needs urgent care.

MRI helps define the affected area and guide surgical planning. When feasible, tissue is examined by a neuropathologist and tested for relevant molecular features. The final integrated diagnosis distinguishes glioblastoma from other brain tumors, including pediatric-type high-grade gliomas. IDH-wildtype status alone does not establish glioblastoma in every brain tumor.

What grade and molecular tests mean

CNS WHO grade 4 describes the tumor's biological classification. It is not equivalent to stage IV cancer that has spread from another organ. Glioblastoma begins in the brain and can infiltrate surrounding tissue beyond what can be removed safely.

MGMT promoter methylation provides information relevant to temozolomide treatment decisions, especially when health or tolerance limits the options. It does not guarantee benefit or determine an individual's prognosis alone. Broader molecular testing is considered when it can answer a clinical question or support eligibility for a suitable trial.

Treatment and continuing care

Surgery aims to remove as much tumor as safely possible while preserving function. Biopsy may be appropriate when removal would pose excessive risk. Radiotherapy with temozolomide, followed by further temozolomide, is a common approach for suitable patients. Modified regimens or supportive care may be appropriate according to health, preferences and expected treatment burden.

Follow-up includes clinical review and imaging interpreted in the treatment context. If progression is suspected, the team reviews further treatment and trial options individually. Seizure care, rehabilitation, psychological support and relief of symptoms are also part of care.

For a review, ask which original MRI files, tissue materials and molecular reports are needed. List previous treatments and current medicines. Clarify who will coordinate care through the oncology service and whom to contact if symptoms change.

Frequently asked questions

Is glioblastoma the same as every high-grade glioma?

No. Molecularly defined tumor types differ, and adult and pediatric classifications must be distinguished.

Can MRI alone confirm glioblastoma?

No. MRI can suggest the diagnosis; confirmation usually requires tissue and molecular assessment when feasible.

Does complete removal guarantee cure?

No. Infiltrating tumor cells can remain beyond the visible lesion. Surgery is considered within a broader treatment plan.

Does everyone receive the same treatment?

No. The team considers diagnosis, function, general health, biomarkers, previous treatment and the person's goals.